September 23, 2008
Rx100 Rescues Life If Administered ~26 Hours After Exposure to Lethal, Whole-Body Radiation!
JOHNSON CITY, Tenn., Sept. 23 /PRNewswire/ -- Studies conducted to date have demonstrated that even though a single, subcutaneous dose of Rx100 is administered some 26 hours after exposure to lethal, whole-body radiation, a relatively high percentage of test animals survive having received no support other than normal food and water (NOTE: Test animals in many survival protocols receive additional supportive care in the form of antibiotics, etc.). "Preliminary studies suggest a wider time window may well be achievable," stated RxBio Chairman and CEO Dr. W. Shannon McCool.
In addition, an enhancement of total white blood cell and platelet counts in peripheral blood and significant increase of crypt regeneration in the small intestine has been observed following treatment with Rx100. Pharmacokinetic studies have revealed that Rx100 has a long serum half-life.
According to Gabor Tigyi, M.D., Ph.D., Chairman of the Department of Physiology at the University of Tennessee Health Science Center, and coinventor of the drug: "Rx100 is unique among radiation countermeasure agents in that: it is an analog of an endogenous, prosurvival molecule that boosts natural mechanisms that promote and sustain cell survival while inhibiting the cascade leading to programmed cell death. While other agents shut down essential cellular-signaling mechanisms involved in radiation-induced cellular injury, tend to lack specificity, and may deliver unacceptable toxicities, Rx100 is a specific activator of natural, nontoxic, protective mechanisms of cell survival."
Rx100 is unique as a radioprotectant / radiomitigator in that it can be administered orally or by subcutaneous injection and it possesses a variety of favorable product characteristics that make it an ideal agent for use as a radiation countermeasure.
Rx100 is a potent radiomitigator that also ameliorates radiation- associated hematopoietic syndrome as well as gastrointestinal syndrome.
CONTACT: W. Shannon McCool, D.Ph., RxBio, Inc., +1-423-928-3330; fax:+1-423-282-6602, [email protected]
Web site: http://www.rxbio.com/